FBRX
Forte Biosciences IncPINK
Healthcare • Biotechnology
Updated 4 days ago
Coverage limited
$76.99+0.03%
Close Aug 26, 2026
- Market cap
- $1.07B
- 1 month
- +0.4%
- 3 months
- +258.6%
- 1 year
- —
- 52-week range
- $10.30$76.99
- Dividend
- No payments on record
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$87.94M
- Free cash flow
- -$72.03M
- Book value
- $183.79M
- Total debt
- —
- P/E
- —
- Price / sales
- —
- Price / book
- —
- FCF yield
- —
- Net margin
- —
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if FBRX is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
21 top institutions tracked
as of 2026-Q2 (filed 2026-09-23)
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 0
Largest 13-F holders · Q2 2026
86 filers reported a long position in FBRX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FEDERATED HERMES, INC. | $44.8M | 2.1M | +19.5% |
| ORBIMED ADVISORS LLC | $33.5M | 1.6M | +31.8% |
| FRED ALGER MANAGEMENT, LLC | $30.6M | 1.4M | +13% |
| Jupiter Topco LLC | $29.2M | 1.4M | — |
| BlackRock, Inc. | $26M | 1.2M | +1,755% |
| Affinity Asset Advisors, LLC | $24.3M | 1.1M | +13.2% |
| MPM BioImpact LLC | $21M | 987.4K | -1.3% |
| TCG Crossover Management, LLC | $19.6M | 920K | New |
| VANGUARD CAPITAL MANAGEMENT LLC | $18.3M | 861.7K | +62.1% |
| Woodline Partners LP | $15.1M | 712.8K | +114.7% |
Get the Full Analysis for FBRX
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.